(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride | |
---|---|
Trade Name | |
Orphan Indication | Primary sclerosing cholangitis |
USA Market Approval | USA |
USA Designation Date | 2013-09-04 00:00:00 |
Sponsor | Shire Human Genetic Therapies, Inc.;300 Shire Way;Lexington, California, 02421 |